Piet Ost: RADIOSA trial at ESTRO24

Piet Ost, Assistant Professor of Radiation Oncology at Ghent University, shared on X/Twitter:

“RADIOSA trial:

• oligorecurrent PCa SBRT vs SBRT + 6 months ADT
• ADT improved bRFS and cRFS
• more polymetastatic recurrences in the ADT arm.
• would love to see eugonad-relapse free survival.
• will be interesting to see QoL data and compare with the DART trial.

ESTRO24.”

Source: Piet Ost/X